Christodoulos Dolapsakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christodoulos Dolapsakis has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Evangelia Margellou
Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece
2 shared publications- Natalia G. Vallianou
First Department of Internal Medicine, Sismanogleio General Hospital, Athens, Greece
2 shared publications Aikaterini Katsandri
3rd Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece
1 shared publication- Andreas Kousios
West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
1 shared publication Andreas Panagopoulos
Evangelismos General Hospital, 3rd Department of Internal Medicine, Athens, Greece
1 shared publicationArgiro Gogou
1 shared publication
Latest Publications
- Open Access
- 29 January 2025
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 12 (2) , 005169
Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have complex interactions with bone metabolism, including an increase in parathyroid hormone (PTH) levels. Here we report a case of a SGLT2 inhibitor-induced hypercalcemia due to primary hyperparathyroidism. In the subset of patients with normocalcemic primary hyperparathyroidism, SGLT2 inhibitor initiation can unmask the disorder causing overt hypercalcaemic hyperparathyroidism. Although normocalcemic primary hyperparathyroidism is a rare entity, we propose obtaining a baseline PTH level before starting a SGLT2 inhibitor in patients with calcium levels in the upper limit of normal and normal total 25-hydroxyvitamin D levels, especially if they are under vitamin D supplementation. PTH should be rechecked in order to exclude overt primary hyperparathyroidism.
- 29 January 2025
- Published by SMC Media in European Journal of Case Reports in Internal Medicine
- Vol. 12 (2) , 005169
Open AccessUnmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have complex interactions with bone metabolism, including an increase in parathyroid hormone (PTH) levels. Here we report a case of a SGLT2 inhibitor-induced hypercalcemia due to primary hyperparathyroidism. In the subset of patients with normocalcemic primary hyperparathyroidism, SGLT2 inhibitor initiation can unmask the disorder causing overt hypercalcaemic hyperparathyroidism. Although normocalcemic primary hyperparathyroidism is a rare entity, we propose obtaining a baseline PTH level before starting a SGLT2 inhibitor in patients with calcium levels in the upper limit of normal and normal total 25-hydroxyvitamin D levels, especially if they are under vitamin D supplementation. PTH should be rechecked in order to exclude overt primary hyperparathyroidism.
- 31 May 2020
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 192 (22) , E608
A giant splenic artery aneurysm
- 31 May 2020
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 192 (22) , E608
A giant splenic artery aneurysm
- Open Access
- 26 February 2020
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 20 (1) , 84-86
An HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone
Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD. Case Presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles. Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.
- 26 February 2020
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 20 (1) , 84-86
Open AccessAn HHV-8 Positive HIV Negative Multicentric Castleman’s Disease, who Responded well to Rituximab Alone
Background: Multicentric Castleman Disease (MCD) presents with enlarged lymph nodes in multiple regions and systemic inflammatory symptoms, due to the dysregulation of cytokines, most commonly interleukin-6 (IL-6). Human herpes virus-8 (HHV-8) is strongly related to MCD (HHV-8-associated MCD) and is being implicated in cytokine dysregulation in patients, the majority of whom are HIV positive or immunosuppressed. Preferred treatment of HHV-8- associated MCD depends on the presence or not of concurrent Kaposi sarcoma and on whether the patient has life-threatening organ failure or poor performance status thought to be related to HHV- 8-associated MCD. Case Presentation: Herein, we describe a female patient with HHV-8 positive, HIV negative MCD, who responded well to the administration of rituximab once weekly for four weeks alone for three cycles. Conclusion: HHV-8 positive, HIV negative MCD treatment modalities are only anecdotal due to the rarity of this form of MCD. Administration of rituximab alone seems to be beneficial among patients with good performance status and the absence of life-threatening organ failure in cases of HHV-8 positive, HIV negative MCD.
- 1 June 2019
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 56 (6) , 713-714
Spontaneous Retroperitoneal Hemorrhage
- 1 June 2019
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 56 (6) , 713-714
Spontaneous Retroperitoneal Hemorrhage
- 1 March 2019
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 61, e5-e6
A jelly belly: An unusual cause of ascites
- 1 March 2019
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 61, e5-e6
A jelly belly: An unusual cause of ascites
- 31 January 2019
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 357 (6) , 517-518
Fever and Leukemoid Reaction as the Presenting Manifestation of Disseminated Parotid Gland Carcinoma
- 31 January 2019
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 357 (6) , 517-518
Fever and Leukemoid Reaction as the Presenting Manifestation of Disseminated Parotid Gland Carcinoma
- 29 January 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (1) , e227302
Cavernous sinus thrombosis due to ipsilateral sphenoid sinusitis
We report a case of septic thrombosis of the right cavernous sinus in a diabetic woman in her late 70’s due to ipsilateral sphenoid sinusitis. The diagnosis was delayed and made only after the abrupt and dramatic appearance of the manifestations of sinus thrombosis. The patient developed, among the other symptoms, right peripheral facial palsy, which is a very rare manifestation in cavernous sinus thrombosis (CST). She was treated with broad-spectrum antibiotics and enoxaparin. The day of the scheduled drainage of sphenoid sinus—24 hours after the initiation of anticoagulation—she developed fatal subarachnoid haemorrhage. Our case demonstrates the difficulty of timely diagnosis of acute sphenoid sinusitis which has emerged as the most common primary infectious source potentially leading in CST. It also underscores the uncertainty concerning the use of anticoagulation in cerebral sinus thrombosis of infectious origin.
- 29 January 2019
- Published by BMJ in BMJ Case Reports
- Vol. 12 (1) , e227302
Cavernous sinus thrombosis due to ipsilateral sphenoid sinusitis
We report a case of septic thrombosis of the right cavernous sinus in a diabetic woman in her late 70’s due to ipsilateral sphenoid sinusitis. The diagnosis was delayed and made only after the abrupt and dramatic appearance of the manifestations of sinus thrombosis. The patient developed, among the other symptoms, right peripheral facial palsy, which is a very rare manifestation in cavernous sinus thrombosis (CST). She was treated with broad-spectrum antibiotics and enoxaparin. The day of the scheduled drainage of sphenoid sinus—24 hours after the initiation of anticoagulation—she developed fatal subarachnoid haemorrhage. Our case demonstrates the difficulty of timely diagnosis of acute sphenoid sinusitis which has emerged as the most common primary infectious source potentially leading in CST. It also underscores the uncertainty concerning the use of anticoagulation in cerebral sinus thrombosis of infectious origin.
- Open Access
- 1 January 2019
- Published by Medknow in Lung India
- Vol. 36 (4) , 370-371
Crack lung: A case of acute pulmonary cocaine toxicity
Lung India, Official publication of the Indian Chest Society
- 1 January 2019
- Published by Medknow in Lung India
- Vol. 36 (4) , 370-371
Open AccessCrack lung: A case of acute pulmonary cocaine toxicity
Lung India, Official publication of the Indian Chest Society
- 7 September 2016
- Vol. 12 (529) , 1453-1459
[Direct oral anticoagulants : some practical considerations].
Prevention and management of thromboembolic events are historically based on the use of anti-vitamines K (AVK) and heparins. Since 2009, emerging direct oral anticoagulants (DOAC) with successive validated indications, changed progressively the way of managing oral anticoagulation. The main advantages of this new generation of medication are a better safety profile and the lack of need for monitoring anticoagulation activity. However, a number of situations in clinical practice still require careful use of these DOAC. This article review some practical considerations and specific situations of hospital and ambulatory settings.
- 7 September 2016
- Vol. 12 (529) , 1453-1459
[Direct oral anticoagulants : some practical considerations].
Prevention and management of thromboembolic events are historically based on the use of anti-vitamines K (AVK) and heparins. Since 2009, emerging direct oral anticoagulants (DOAC) with successive validated indications, changed progressively the way of managing oral anticoagulation. The main advantages of this new generation of medication are a better safety profile and the lack of need for monitoring anticoagulation activity. However, a number of situations in clinical practice still require careful use of these DOAC. This article review some practical considerations and specific situations of hospital and ambulatory settings.
- 1 October 2011
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 22, S26
NON-TYPHOIDAL SALMONELLA BACTEREMIA IN A PATIENT WITH A VALVE REPLACEMENT
- 1 October 2011
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 22, S26
NON-TYPHOIDAL SALMONELLA BACTEREMIA IN A PATIENT WITH A VALVE REPLACEMENT